FDA-cleared profile

AutoDensity

Eos Imaging · X-ray/Radiography · FDA-cleared (510(k))

AutoDensity estimates L1-L4 spine bone-mineral density from EOSedge dual-energy AP radiographs for opportunistic orthopedic pre-surgical assessment; it is not a replacement for DXA confirmation.

Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
X-ray/Radiography · Spine
Key limitation
AutoDensity is not a DXA replacement; patients with suspected low bone density require confirmation using the standard clinical pathway.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyX-ray/Radiography · Spine
  • Workflow roleMedical-image processing, measurement, quantification, visualization, and reporting support.
  • Required inputDual-energy X-ray images from EOSedge systems.
  • Output and human actionPreviews of the images used to compute lumbar-spine BMD and BMD measurements for L1, L2, L3, and L4, including total BMD.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AutoDensity estimates L1-L4 spine bone-mineral density from EOSedge dual-energy AP radiographs for opportunistic orthopedic pre-surgical assessment; it is not a replacement for DXA confirmation.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Medical-image processing, measurement, quantification, visualization, and reporting support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Dual-energy X-ray images from EOSedge systems.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet identifies dual-energy X-ray images from EOSedge systems as the input; it does not establish the dossier's DICOM and release-specific user-input wording.

Output and clinician action
Previews of the images used to compute lumbar-spine BMD and BMD measurements for L1, L2, L3, and L4, including total BMD.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet describes previews, ROI detection, and BMD measurements for lumbar vertebrae L1 through L4; it does not establish the broader segmentation, visualization, calculation, and professional-review wording.

Care setting
Hospital or outpatient imaging analysis and reporting environments.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
AutoDensity is not a DXA replacement; patients with suspected low bone density require confirmation using the standard clinical pathway.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
K251078 reports a 30-subject precision study and 253-subject agreement study. Within-subject CV was 2.23%; mean bias versus reference was 0.045 g/cm2 with limits of agreement from -0.088 to 0.178 g/cm2.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K251078 reports a 30-subject precision study and 253-subject agreement study. Within-subject CV was 2.23%; mean bias versus reference was 0.045 g/cm2 with limits of agreement from -0.088 to 0.178 g/cm2.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Within-subject coefficient of variation

2.23 %

  • EndpointRepeat AutoDensity precision
  • PopulationAutoDensity
  • Tested versionAutoDensity release cleared in K251078

Mean BMD bias

0.045 g/cm2

  • EndpointAgreement with reference
  • PopulationAutoDensity
  • Tested versionAutoDensity release cleared in K251078

K251078 FDA performance package for AutoDensity

  • DesignManufacturer precision and agreement studies
  • PopulationAdults undergoing EOSedge spine radiography and reference bone-density assessment
  • Scopeexact submission
  • Tested versionAutoDensity release cleared in K251078
  • Samplen=253
  • IndependenceSponsor or vendor study

K251078

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251078 by exact submission identifier. This does not exclude product-family or later safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Dual-energy X-ray images from EOSedge systems.

    Scope: Exact FDA submission. The exact packet identifies dual-energy X-ray images from EOSedge systems as the input; it does not establish the dossier's DICOM and release-specific user-input wording.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K251078: AutoDensity

  2. Routing

    Source context, not route validation: DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K251078: AutoDensity · EOS product documentation

  3. AI processing

    Source context, not route validation: Software on a workstation, server, or supported virtual environment with release-specific licenses.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K251078: AutoDensity · EOS product documentation

  4. Returned objects

    Source context, not route validation: Previews of the images used to compute lumbar-spine BMD and BMD measurements for L1, L2, L3, and L4, including total BMD.

    Scope: Exact FDA submission. The exact packet describes previews, ROI detection, and BMD measurements for lumbar vertebrae L1 through L4; it does not establish the broader segmentation, visualization, calculation, and professional-review wording.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K251078: AutoDensity

  5. Viewer/worklist/report

    Unresolved route: Previews of the images used to compute lumbar-spine BMD and BMD measurements for L1, L2, L3, and L4, including total BMD.

    Scope: Exact FDA submission. The exact packet describes previews, ROI detection, and BMD measurements for lumbar vertebrae L1 through L4; it does not establish the broader segmentation, visualization, calculation, and professional-review wording.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K251078: AutoDensity

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software on a workstation, server, or supported virtual environment with release-specific licenses.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: AutoDensity is not a DXA replacement; patients with suspected low bone density require confirmation using the standard clinical pathway.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K251078 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AutoDensity is not a DXA replacement; patients with suspected low bone density require confirmation using the standard clinical pathway.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: AutoDensity is not a DXA replacement; patients with suspected low bone density require confirmation using the standard clinical pathway.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251078
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Spine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-11-14
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
10Source classes checked
5Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 5 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 2 history items

Source ledger

  1. FDA K251078: AutoDensity

    U.S. Food and Drug Administration - Published 2025-11-14 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, limitations, evidenceSummary, input, output, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. EOS product documentation

    EOS imaging - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

Research history

  1. K251078 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K241593

BoneMetrics (US)

Gleamer SAS

Authorized purpose: BoneMetrics is fully automated software that assists trained radiology professionals with Cobb-angle measurement on frontal spine radiographs in patients aged four years or older with suspected or present spinal deformity or scoliosis; it is not a replacement for complete evaluation or sole diagnosis.

Modality
X-ray/Radiography
Anatomy
Spine
Decision
2025-02-05
FDA-cleared K222176

BoneView

Gleamer

Authorized purpose: BoneView 1.1-US analyzes eligible 2D radiographs as a concurrent fracture-reading aid. Limb examinations apply to patients aged 2 years and older; pelvis, hip, femur, ribs, thoracic spine, and lumbosacral spine are limited to adults older than 21 years. Clinical users retain diagnostic and patient-management responsibility.

Modality
X-ray/Radiography
Anatomy
Spine
Decision
2023-03-02
FDA-cleared K221632

Spine CAMP™

Medical Metrics, Inc.

Authorized purpose: Automated analysis of sagittal lumbar and cervical spine radiographs to produce static and motion metrics supporting qualified practitioners' decision-making in skeletally mature patients age 18 and above.

Modality
X-ray/Radiography
Anatomy
Spine
Decision
2022-10-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history